This trial is a translational, open-label, monocentric and prospective cohort study of participants with breast cancer aiming to create a combined ESPRESSO (= organelle properties) phenotype and spatial proteomics data collection encompassing four cohorts:
* TN eBC = cohort A, * HER2+ eBC = cohort B, * Luminal eBC = cohort C, * dnMBC = cohort D. In total 1050 participants will be enrolled in the study. Laboratory analysis (including ESPRESSO technique) will be conducted on the biological specimen collected during this study.
The primary objective is to describe the amount of fatty acids accumulated in lipid droplets, within the four cohorts. As a secondary objective, the analysis will expand to other organelles like lysosomal acidity and nuclear organization.
The study is due to last 9 years (4 years of recruitment and 5 years of study participation)
Patient (women or men) with histologically documented breast cancer
Early Breast Cancer (eBC) or de novo metastatic BC (dnMBC), regardless the immunohistochemical subtype: Triple Negative BC (ER-negative [<10%], PR-negative [<10%] and HER2-negative [i.e. null, ultra-low or low] BC); HER2-positive BC: HER2 overexpression score 3+ or ERBB2 amplification whatever ER/PR expression and proliferation level; Luminal A-like BC: low to moderately proliferative (Ki67<20%) ER-positive (≥ 10%) PR-positive (≥ 20%) BC and low proliferative (Ki67< 14%) ER-positive PR-negative (< 20%) BC; Luminal B-like BC: highly proliferative (Ki67≥ 20%) ER-positive, PR-positive BC or moderately proliferative (14% ≤ Ki67< 20%) ER-positive PR-negative (<20%) BC
Age ≥ 18 years at the time of study entry
Patient followed within a standard of care procedure or clinical trial
Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or Hanta virus.
Abnormal coagulation contraindicating biopsy
Previous or on going treatment for the breast cancer
Bone metastases when this is the only site of biopsiable disease for dnMBC patients
Parallel
Tumor biopsy
Other interventionAs fresh tumor material is required for laboratory analysis purposes (ESPRESSO technique), tumor biopsies will be performed specifically for this study.
The amount of fatty acids accumulated in lipid droplets, quantified by the total intensity of a lipid-droplet specific fluorescent dye in the four cohorts
Pathological response will be assessed using residual cancer burden (RCB) index 17
* RCB-0: pathologic complete response (pCR) * RCB-I : minimal burden * RCB-II: moderate burden * RCB-III : extensive burden
Event-free survival (EFS) is defined as the time from inclusion until relapse (local, regional or distant) or death from any cause for eBC.
Participants alive and relapse-free will be censored at last follow-up news or at initiation of new anticancer therapy
First line Progression-free survival (PFS1) is defined as the time from inclusion until progression or death from any cause for dnMBC
Participants alive and progression-free will be censored at last follow-up news or at initiation of new anticancer therapy
Click on the lead sponsor to view all of their trials.
